(IN BRIEF) Sanofi has completed the acquisition of DR-0201 from Dren Bio, now renamed SAR448501, to enhance its immunology pipeline. This bispecific myeloid cell engager, which has shown promising results in B-cell depletion, may offer potential breakthroughs in autoimmune diseases, … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged acquisition, antibody therapeutics, autoimmune diseases, B cell depletion, biopharmaceuticals, bispecific myeloid cell engager, clinical-stage, DR-0201, Dren Bio, immunology, lupus, partnership, phagocytosis, Sanofi, SAR448501, therapeutics
(IN BRIEF) CVC Strategic Opportunities II has successfully exited its investment in Genetic S.p.A., a pharmaceutical CDMO specializing in Respiratory, Ophthalmic, and Oncology therapeutic products. The exit sees NB Renaissance and NB Aurora joining the Pavese family as shareholders. Under … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Italy, Luxembourg, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged CVC Strategic Opportunities II, exit, FRM Tax, Genetic S.p.A., international expansion, investment, NB Aurora, NB Renaissance, oncology, Ophthalmic, partnership, Pavese family, PedersoliGattai, pharmaceutical CDMO, pharmaceutical industry, Product Development, PwC, respiratory, Rocco Pavese, Rothschild & Co., strategic growth
(IN BRIEF) NIB has financed the Gene Therapy Centre in Lithuania, a groundbreaking facility advancing gene therapy research and manufacturing. Opened in September, it is a critical part of Lithuania’s life sciences sector, contributing to the country’s goal of growing … Read the full press release
Posted in Banks, Business, Economy, Environment, Financial, Finland, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Lithuania, Management, News, Pharma & Biotech, Science, Technology
Tagged BIO CITY, biotechnology, Celltechna, economic growth, gene therapy, Gene Therapy Centre, investments, life sciences, Lithuania, NIB, Nordic-Baltic region, partnership, research and manufacturing, strategic partnerships, sustainability
(IN BRIEF) GSK has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Blenrep combinations to treat adults with relapsed or refractory multiple myeloma. The approval follows positive results from the DREAMM-7 and DREAMM-8 phase III trials, … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged anti-BCMA, antibody-drug conjugate, Blenrep, bortezomib, chemotherapy, clinical efficacy, clinical trials, DREAMM-7, DREAMM-8, global markets, GSK, Japan approval, Multiple Myeloma, oncology, orphan drug designation, overall survival, partnership, PDUFA, pomalidomide, progression-free survival, regulatory approval, sustainability, treatment options
(IN BRIEF) CTP has successfully developed a state-of-the-art 18,000 sqm production facility for SCHOTT Pharma at CTPark Jagodina, Serbia, where high-quality glass ampoules for vaccines and medications will be produced. This facility is a significant addition to SCHOTT Pharma’s global … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Netherlands, News, Pharma & Biotech, Real Estate, Serbia, Technology, Transportation & Logistics
Tagged BREEAM certification, CTP, CTPark Jagodina, EU markets, glass ampoules, industrial property, logistics, manufacturing facility, partnership, real estate development, SCHOTT Pharma, SERBIA, Serbia’s economy, Skilled Workforce, supply chain, sustainability, sustainable construction, vaccines
(IN BRIEF) Researchers from the University of Copenhagen have made a breakthrough in the biosynthetic production of Taxol, a widely used chemotherapy drug. By identifying the enzymes responsible for the final steps in the biosynthetic pathway of Taxol, the team … Read the full press release
Posted in Business, Denmark, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged biosynthetic production, biotechnology, cancer treatment, chemotherapy, environmental sustainability, Feiyan Liang, ovarian cancer, Pacific yew tree, pharmaceutical innovation, Sotirios Kampranis, sustainable drug production, sustainable medicine, Taxol, University of Copenhagen
(IN BRIEF) The POTOMAC Phase III trial results show that adding Imfinzi to standard BCG induction and maintenance therapy improves disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC). The combination demonstrated significant benefits over BCG alone, with … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, Bacillus Calmette-Guérin, BCG, bladder cancer, cancer treatment, clinical trial, Cristian Massacesi, disease progression, disease-free survival, durvalumab, high-risk bladder cancer, Imfinzi, immunotherapy, Maria De Santis, NMIBC, non-muscle-invasive bladder cancer, Phase III Trial, POTOMAC
(IN BRIEF) Positive results from the Phase III KALOS and LOGOS trials show that AstraZeneca’s Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) significantly improves lung function in patients with uncontrolled asthma, compared to dual-combination ICS/LABA therapy. The trials demonstrate the potential of Breztri … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Alberto Papi, asthma, AstraZeneca, BioPharmaceuticals R&D, Breztri Aerosphere, budesonide/glycopyrronium/formoterol, chronic respiratory disease, clinical trials, COPD, global asthma statistics, ICS/LABA, KALOS, LOGOS, lung function, Phase III, regulatory authorities, Sharon Barr, triple-combination therapy
(IN BRIEF) Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in consumer healthcare. Sanofi retains a significant 48.2% stake, while Bpifrance will hold 1.8% and join … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Allegra, biopharma, Bpifrance, CD&R expertise, CDR, consumer health, Consumer HealthCare, Doliprane, Dulcolax, Eric Rouzier, global leader, Healthcare Innovation, healthcare transformation, Julie Van Ongevalle, Opella, OTC, partnership, Paul Hudson, Sanofi, sustainable growth, VMS
(IN BRIEF) Merck has entered into a definitive agreement to acquire SpringWorks Therapeutics for approximately $3.9 billion. This acquisition will significantly enhance Merck’s rare tumor portfolio, adding first-in-class therapies for desmoid tumors and NF1-PN. The deal aligns with Merck’s strategy … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged acquisition, biopharmaceuticals, cancer treatments, desmoid tumors, Healthcare Innovation, M&A, Merck, NF1-PN, partnership, pharmaceutical acquisition, rare tumors, SpringWorks Therapeutics, U.S. healthcare
(IN BRIEF) Sanofi and Sobi have renewed their partnership with the World Federation of Hemophilia (WFH) to support the WFH Humanitarian Aid Program for up to five years. The new agreement includes the donation of up to 100 million international … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, News, Non Profit, Pharma & Biotech, Science, Technology
Tagged Alaa Hamed, bleeding disorders, Cesar Garrido, factor therapy, Foundation S, global health, healthcare professionals, hemophilia, humanitarian aid, Lydia Abad-Franch, Mark Skinner, medical collaboration, partnership, rare diseases, Sanofi, Sobi, treatment for all, WFH, World Federation of Hemophilia
(IN BRIEF) Evotec SE has reached key milestones in its molecular glue degrader collaboration with Bristol Myers Squibb, earning $75 million in performance- and program-based payments. The partnership, built on Evotec’s AI-driven drug discovery platforms and BMS’s CELMoD™ technology, continues … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged AI drug discovery, biotech partnerships, Bristol-Myers Squibb, CELMoD, Cord Dohrmann, E3 ligase, Evotec, first-in-class, milestone payments, molecular glue degraders, oncology, PanOmics, partnership, pharmaceutical R&D, protein degradation, targeted therapies, unmet medical needs
(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Acute myeloid leukemia, cancer treatment, clinical trials, CXCR4, Dirk Pleimes, Eckert & Ziegler, EZR, Ga68-PentixaFor, GMP manufacturing, Harald Hasselmann, lymphoma, Myeloma, nuclear medicine, Pentixapharm, radiopharmaceuticals, radiotherapy, solid tumors, targeted therapy, theranostics, Y90-PentixaTher
(IN BRIEF) Basilea Pharmaceutica has received a CHF 1.7 million milestone payment from its partner Asahi Kasei Pharma following continued strong sales of Cresemba® in Japan—marking the second consecutive quarterly milestone. Cresemba, now marketed in over 70 countries, achieved USD … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged AKP, antifungal treatment, Asahi Kasei Pharma, aspergillosis, azole antifungal, Basilea Pharmaceutica, biopharmaceuticals, branded antifungal leader, Cresemba®, cryptococcosis, David Veitch, fungal infection therapies, global antifungal sales, intravenous antifungal, invasive fungal infections, Isavuconazole, Japan pharmaceutical market, Japanese drug market, milestone payment, mucormycosis, oral antifungal, partnership
(IN BRIEF) Roche has launched a CE-marked Chest Pain Triage algorithm developed with Universitätsklinikum Heidelberg to improve emergency diagnosis of chest pain. Integrated into the navify® Algorithm Suite, the tool uses high-sensitivity cardiac troponin testing and ESC guidelines to support … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged acute coronary syndrome, AI in healthcare, cardiac diagnostics, cardiovascular disease, CE-marked IVD, Chest Pain Triage Algorithm, digital diagnostics, digital health, EHR integration, emergency department, ESC guidelines, Healthcare Innovation, high-sensitivity troponin, hospital workflow optimization, Matt Sause, medical device, navify Algorithm Suite, patient triage, Roche, Universitätsklinikum Heidelberg
(IN BRIEF) CCRM Nordic is building a new ATMP production facility in GoCo Health Innovation City, Sweden, to support the development of next-generation gene, cell, and tissue-based therapies. AFRY will serve as engineering partner and project manager, leading the design, … Read the full press release
Posted in Business, Environment, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, Pharma & Biotech, Science, Sweden, Technology
Tagged advanced therapy medicinal products, AFRY, ATMP, biotechnology innovation, CCRM Nordic, cell therapy, engineering partner, Fredrik Wessberg, future-proof lab design, gene therapy, GMP compliance, GoCo Health Innovation City, Martin Öman, Mölndal, partnership, personalised medicine, pharmaceutical manufacturing, project management, sustainability, sustainable pharmaceutical production, Sweden healthcare strategy
(IN BRIEF) Boehringer Ingelheim has entered into a multi-year collaboration with Cue Biopharma to develop and commercialize CUE-501, a first-in-class bispecific compound designed to selectively deplete harmful B cells in autoimmune diseases. The innovative therapy uses Cue’s Immuno-STAT™ platform to … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged autoimmune diseases, B cell depletion, biologics innovation, biopharma collaboration, bispecific compound, Boehringer Ingelheim, Carine Boustany, chronic disease treatment, Cue Biopharma, CUE-501, Daniel Passeri, drug development, Immuno-STAT, Immuno-STAT platform, immunology pipeline, inflammatory diseases, licensing agreement, memory T cells, milestone payments, partnership, precision medicine, royalty payments, strategic partnership, T cell engagers, targeted biologics, up-front payment
(IN BRIEF) At ESCMID Global 2025 in Vienna, AstraZeneca will present a comprehensive data package from its Vaccines & Immune Therapies portfolio, featuring 13 abstracts across oral and poster presentations. The Company aims to demonstrate its progress in developing innovative … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, AZD6563, Benjamin Moutier, bronchiectasis, COVID-19, ESCMID Global 2025, Fluenz, FluMist, hMPV, immunizations, infectious diseases, Klebsiella pneumoniae, monoclonal antibodies, mRNA, MRSA, preclinical data, Pseudomonas aeruginosa, Real-World Data, respiratory viral infections, RSV, serious bacterial infections, Staphylococcus aureus, Vaccines & Immune Therapies, variant-agnostic threshold, Vienna
(IN BRIEF) Roche presented new data at the AD/PD 2025 International Conference demonstrating that trontinemab, in its Phase Ib/IIa Brainshuttle™ AD study, achieves rapid and dose-dependent reductions of amyloid plaques in the brain, with significant biomarker improvements observed in fluid … Read the full press release
Posted in Austria, Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Media, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged AD/PD 2025 International Conference, Alzheimer’s disease, amyloid plaques, ARIA-E, biomarkers, Brainshuttle AD study, cognitive impairment, diagnostic solutions, dose-dependent reduction, Elecsys pTau181 plasma test, Levi Garraway, neurogranin, Phase Ib/IIa study, Phase III programme, pTau181, pTau217, Roche, total tau, trontinemab
(IN BRIEF) Effective 3 April 2025, Novo Nordisk will undergo key changes in its Executive Management. Camilla Sylvest, a long-time leader with 28 years at the company, has decided to step down. In response, Ludovic Helfgott will assume expanded responsibilities … Read the full press release
Posted in Business, Denmark, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged appointment, Camilla Sylvest departure, executive management, Executive Team, Global Communication, IT & Environmental Affairs, leadership, Leadership changes, Ludovic Helfgott, Novo Nordisk, organizational restructuring, Product & Portfolio Strategy, Quality, strategic leadership, Tania Sabroe, Thilde Hummel Bøgebjerg
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?